Search results
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 3 months agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Zacks via Yahoo Finance· 3 months agoGSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 2 months agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Glaxo (GSK) Up 1.6% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 2 weeks agoIt has been about a month since the last earnings report for GSK (GSK). Shares have added about 1.6%...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
Zacks via Yahoo Finance· 1 month agoGSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The...